Objective Responses Observed in Rare Thyroid Tumors With Dual Checkpoint Blockade
Dual anti-CTLA-4 and anti-PD-1 blockade with the combination of ipilimumab (Yervoy) with nivolumab (Opdivo) induced an objective response rate (ORR) of 12% as treatment of patients with thyroid can…
